NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-141 from the NIH Guide for Grants and Contracts. Title: NIDCR Dual Degree Dentist-Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required) Purpose The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person- months effort (25% effort). in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion Clinical Trial Required FOA (PAR-18-432). Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA (PAR-19-NNN)
Funding Opportunity PAR-19-144 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person- months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial or basic experimental study with humans led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator should apply to one of the companion FOAs. Applicants proposing studies conducted with specific applications toward processes or products in mind should submit to the companion Clinical Trial Required FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as prospective basic science studies involving human participants should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-NNN).
Funding Opportunity PAR-19-143 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion Clinical Trials Required FOA.
Funding Opportunity PAR-19-138 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of in vitro platforms that recapitulate components of the human immune system. Applications that qualify for this funding will focus on engineering 3-D in vitro microphysiological immune system tissues, adding immune system responsiveness to existing in vitro platforms, and/or in vitro modeling autoimmune diseases and inflammation.
Funding Opportunity RFA-EB-18-002 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support non-commercial lab-to-user dissemination of novel, reliable imaging and bioengineering technologies, including devices, software, methods, chemical agents, etc. Proposed technologies should have been prototyped, validated, and are potentially highly impactful to the research community. However, their beyond-the-lab dissemination via commercialization or industry partnership is not anticipated. Projects should focus on transforming functioning prototypes to usable tools and delivering them to end users for high-quality research in a reliable manner. Related activities may include, but are not limited to, quality control, scale-up production, user training, and technical improvements that are within the scope of the prototyped technology and limited to applying proven techniques or existing resources. Projects that involve clinical trials, commercialization, academic-industry partnership, or service using existing equipment are not responsive to this FOA.
Funding Opportunity PAR-19-137 from the NIH Guide for Grants and Contracts. The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).
Notice NOT-HL-18-665 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-135 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduates Schools of Arts and Sciences is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools of arts and sciences to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.
Funding Opportunity PAR-19-134 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools of Arts and Sciences is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools of arts and sciences to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years.
Funding Opportunity PAR-19-136 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 1224 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.
Funding Opportunity PAR-19-133 from the NIH Guide for Grants and Contracts. The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.
Funding Opportunity RFA-DA-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to take part in the creation of Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (SUDs). The purpose of this Funding Opportunity Announcement (FOA) is to support the creation of Laboratories with expertise and resources to conduct early clinical evaluation of potential pharmacotherapies for Substance Use Disorders (SUDs). The goal is to accelerate the clinical development of medications to treat Substance Use Disorders (SUDs) by supporting Laboratories with expertise and resources to timely and efficiently conducting FDA-defined Phase 1 and/or Phase 2 clinical trials of new or repurposed compounds to treat SUDs. the clinical development of medications to treat Substance Use Disorders (SUD) by supporting laboratories with the expertise and resources to timely and efficiently conduct early (Phase 1 or Phase 2) clinical trials of potential pharmacotherapies for SUDs.
Notice NOT-MH-19-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-029 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes, Centers, and Programs, NIAAA, NICHD, NIMH, NIMHD, NINDS, and ECHO intend to publish a funding opportunity announcement to solicit applications to propose and test the feasibility of research study designs addressing the impact of pre- and postnatal substance exposure (including opioids, opioid treatment medications, cannabis, alcohol, tobacco, other prescription or illicit substances, alone or in combination) on brain, social, and behavioral development, mental illness, and substance use. In addition to planning and testing the feasibility of study designs, awardees will be expected to participate in several grantee meetings to share lessons learned and begin to develop the network of sites needed to conduct this study.
Funding Opportunity RFA-DA-19-036 from the NIH Guide for Grants and Contracts. NIDA and the following NIH Institutes, Centers, and Programs, NIAAA, NICHD, NIMH, NIMHD, NINDS, and ECHO intend to publish a funding opportunity announcement to solicit applications to propose and test the feasibility of research study designs addressing the impact of pre- and postnatal substance exposure (including opioids, opioid treatment medications, cannabis, alcohol, tobacco, other prescription or illicit substances, alone or in combination) on brain, social, and behavioral development, mental illness, and substance use. In addition to planning and testing the feasibility of study designs, awardees will be expected to participate in several grantee meetings to share lessons learned and begin to develop the network of sites needed to conduct this study.
Notice NOT-GM-19-007 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-009 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-007 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-124 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (xxxx).
Funding Opportunity PA-19-125 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (XXXXX).